Multi-Cancer Early Detection: Legislative Landscape— [PODCAST] EP 99

As interest continues to build around multi-cancer early detection, hear what care teams need to know about the technology and the legislative outlook for coverage for this revolutionary testing.

Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!

As interest continues to build around multi-cancer early detection, hear what care teams need to know about the technology and the legislative outlook for coverage for this revolutionary testing. CANCER BUZZ speaks with Anna Howard, principal of Policy Development, Access to and Quality of Care at American Cancer Society – Cancer Action Network, and Jeff Allen, president and CEO of Friends of Cancer Research, about the public health aspects of multi-cancer early detection and current policy/advocacy issues related to this new technology.

Guests

Anna Howard
Principal of Policy Development, Access to and Quality of Care
American Cancer Society Cancer Action Network

“These new tests are really a cutting-edge new technology in the fight against cancer. A lot of research and effort has been given to [understanding] how can we detect cancer sooner because we know that when we detect sooner then the individual has a greater likelihood of surviving that cancer and has more treatment options available to them. So, providing coverage through the [Medicare] Multi-Cancer Early Detection Screening Coverage Act really goes hand in hand with the [Cancer] Moonshot Initiative.”
– Anna Howard

Jeff Allen
President and CEO
Friends of Cancer Research

“If these [multi-cancer early detection] tests do go on to show the ability to improve outcomes for many people with cancer that can be identified earlier and successfully treated then they truly could have a transformative impact on cancer as we know it.”
– Jeff Allen

Resources:

This podcast was created in connection with the education program Multi-Cancer Early Detection: Changes on the Horizon. This project is supported by Exact Sciences.